Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis

Rheumatology

Volumn 49, Issue 9, 2010, Pages 1795-1796

  Belmonte Serrano, Miguel A ^a   Pincus, Theodore ^b  

^a HOSPITAL GENERAL DE CASTELLÓN   (Spain)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; INFLIXIMAB; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ANTIBODY TITER; B LYMPHOCYTE; DISEASE DURATION; DRUG CHOICE; DRUG RESPONSE; DRUG TREATMENT FAILURE; HUMAN; INFLAMMATION; LETTER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; HUMANS; PEPTIDES, CYCLIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955761613     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq141     Document Type: Letter

References (5)

1. Quartuccio L, Fabris M, Salvin S et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology 2009;48:1557-9.
2. Carson DA, Chen PP, Kipps TJ. New roles for rheumatoid factor. J Clin Invest 1991;87:379-83.
3. Bruns A, Nicaise-Roland P, Hayem G et al. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Joint Bone Spine 2009;76:248-53.
4. De Rycke L, Verhelst X, Kruithof E et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 2005;64:299-302.
5. Bos WH, Bartelds GM, Wolbink GJ et al. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol 2008;35: 1972-7.